Epirubicin: Is it like doxorubicin in breast cancer? A clinical review

Q: What is the clinical evidence from this study?

Study design: Review. Population: Breast cancer (early and metastatic). Intervention: Epirubicin vs. Doxorubicin.

Mustafa Khasraw; Richard H. Bell; Chau T. Dang

doi:10.1016/j.breast.2011.12.012

January 18, 2012The BreastOpen Access

Epirubicin: Is it like doxorubicin in breast cancer? A clinical review

View Full Paper

Ask AI

Bookmark

Share

Key result

Epirubicin matches doxorubicin efficacy in breast cancer but carries a distinct cardiotoxicity profile.

Why the study?

Does epirubicin have similar efficacy and a different cardiotoxicity profile compared to doxorubicin in patients with breast cancer?

Key Points

To review clinical evidence comparing the therapeutic efficacy and cardiotoxicity of epirubicin against doxorubicin in patients with early and advanced breast cancer.
Narrative review of published clinical trials evaluating epirubicin as single-agent or combination chemotherapy in early and metastatic breast cancer.
Evaluation of safety and tolerability outcomes across standard regimens and dose-dense chemotherapy schedules.
Epirubicin demonstrates antitumor efficacy equivalent to that of doxorubicin across both early-stage and metastatic disease settings.
Patients treated with epirubicin experience a distinct adverse effect profile marked by reduced cardiotoxicity relative to doxorubicin.
Short-term safety evaluations confirm acceptable cardiac and systemic tolerance during accelerated, dose-dense treatment regimens.

Structured PICO

Does epirubicin have similar efficacy and a different cardiotoxicity profile compared to doxorubicin in patients with breast cancer?

P

Population

Patients with early and metastatic breast cancer

I

Intervention

Epirubicin-containing chemotherapy

C

Comparator

Doxorubicin-containing chemotherapy

O

Outcome

Efficacy and toxicity profile (particularly cardiotoxicity)safety

Epirubicin is an effective alternative to doxorubicin in breast cancer treatment, offering similar efficacy with a distinct cardiotoxicity profile.

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

Epirubicin may be considered to limit cardiotoxicity in breast cancer; leaves open need for prospective randomized confirmation.

Abstract

Anthracyclines are among the most effective chemotherapy treatments available for various types of cancer. The anthracyclines commonly used in treatment of breast cancer are either epirubicin or doxorubicin. Epirubicin is an epimer of doxorubicin with important role in the chemotherapy treatment of both early and metastatic breast cancer. The efficacy of epirubicin is similar to doxorubicin while epirubicin has a different toxicity profile particularly in regard to cardiotoxicity. Epirubicin has been incorporated into most of the anthracycline containing chemotherapy combinations in well-conducted clinical trials involving large numbers of patients. It has also been investigated in studies involving the administration of epirubicin in dose-dense chemotherapy schedules. Short term follow up of dose-dense clinical trials demonstrated safety comparable to that of doxorubicin. This review summarizes published clinical trials investigating epirubicin in the treatment of early and advanced breast cancer.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Khasraw et al. (2012) conducted a review in Breast cancer (early and metastatic). Epirubicin vs. Doxorubicin was evaluated. Epirubicin demonstrates similar efficacy to doxorubicin in the treatment of early and advanced breast cancer, but with a different toxicity profile, particularly regarding cardiotoxicity.

synapsesocial.com/papers/6aa3a3e535cd30b462c61163 https://doi.org/10.1016/j.breast.2011.12.012

View Full Paper

Ask AI

Bookmark

Share

Epirubicin: Is it like doxorubicin in breast cancer? A clinical review

Key Points

Structured PICO

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Epirubicin: Is it like doxorubicin in breast cancer? A clinical review

Key Points

Structured PICO

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading